Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alkermes Plc
(NQ:
ALKS
)
27.07
-0.18 (-0.66%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,234,872
Open
27.33
Bid (Size)
26.81 (2)
Ask (Size)
27.95 (1)
Prev. Close
27.25
Today's Range
26.91 - 27.33
52wk Range
22.01 - 33.71
Shares Outstanding
166,121,384
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
March 27, 2024
When you look at ALKERMES PLC (NASDAQ:ALKS), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
Is NASDAQ:ALKS suited for growth investing?
March 20, 2024
Is ALKERMES PLC (NASDAQ:ALKS) suited for growth investing?
Via
Chartmill
Performance
YTD
-5.42%
-5.42%
1 Month
-8.86%
-8.86%
3 Month
-2.91%
-2.91%
6 Month
-3.87%
-3.87%
1 Year
-3.04%
-3.04%
More News
Read More
The Analyst Verdict: Alkermes In The Eyes Of 4 Experts
March 19, 2024
Via
Benzinga
A Look Into Healthcare Sector Value Stocks
March 11, 2024
Via
Benzinga
Amicus Therapeutics Stock Sees RS Rating Improve To 74
March 05, 2024
Via
Investor's Business Daily
NASDAQ:ALKS stands out as a stock that provides good value for the fundamentals it showcases.
March 05, 2024
Via
Chartmill
Exploring NASDAQ:ALKS's growth characteristics.
February 28, 2024
Via
Chartmill
Earnings Scheduled For February 15, 2024
February 15, 2024
Via
Benzinga
Alkermes's Earnings Outlook
February 14, 2024
Via
Benzinga
Is NASDAQ:ALKS suited for growth investing?
February 07, 2024
Via
Chartmill
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
February 27, 2024
Via
Investor's Business Daily
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
February 23, 2024
Via
Investor's Business Daily
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
February 21, 2024
Via
InvestorPlace
Alkermes Stock Gets RS Rating Upgrade; Profits Surge
February 15, 2024
Via
Investor's Business Daily
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
February 13, 2024
Via
Investor's Business Daily
NASDAQ:ALKS is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
February 12, 2024
Via
Chartmill
NASDAQ:ALKS, an undervalued stock with good fundamentals.
January 19, 2024
Via
Chartmill
Why the growth investor may take a look at ALKERMES PLC (NASDAQ:ALKS).
January 16, 2024
Via
Chartmill
7 Biotech Stocks Fighting America’s Deadliest Diseases
February 08, 2024
Via
InvestorPlace
Madrigal Pharmaceuticals Stock Shows Rising Relative Strength
February 06, 2024
Via
Investor's Business Daily
The 3 Best Biotech Stocks to Invest in for Big Gains in 2024
February 02, 2024
Via
InvestorPlace
3 Top Pharma Stocks to Buy Now: February 2024
February 01, 2024
Via
InvestorPlace
For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering.
February 01, 2024
Via
Chartmill
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
January 23, 2024
Via
Investor's Business Daily
Cassava Sciences Stock Continues Showing Rising Relative Strength
January 16, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.